Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885658 | 0.93 | MEN1 (0.49) | AGTR1MEN1KMT2APSEN1PSEN2 | |
| SCHEMBL2885775 | 0.91 | KMT2A (0.45) | AGTR1MEN1KMT2APSEN1PSEN2 | |
| SCHEMBL12344888 | 0.91 | CA12 (0.41) | AGTR1MEN1KMT2APSEN1PSEN2 | |
| SCHEMBL2885600 | 0.88 | MEN1 (0.45) | AGTR1MEN1KMT2APSEN1PSEN2 | |
| SCHEMBL2886626 | 0.84 | MEN1 (0.43) | AGTR1MEN1KMT2AMTNR1BCYP2C9 | |
| SCHEMBL2886814 | 0.81 | MEN1 (0.44) | AGTR1MEN1KMT2APSEN1PSEN2 | |
| SCHEMBL2887143 | 0.81 | RECQL (0.53) | AGTR1MEN1KMT2APSEN1PSEN2 | |
| SCHEMBL2883359 | 0.79 | SMN1; SMN2 (0.42) | AGTR1MEN1KMT2ACYP2D6CYP2C19 | |
| SCHEMBL2885988 | 0.79 | KMT2A (0.42) | AGTR1MEN1KMT2APSEN1PSEN2 | |
| SCHEMBL2887943 | 0.79 | MEN1 (0.42) | AGTR1MEN1KMT2APSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035429-B1 | FUSED [d]PYRIDAZIN-7-ONES | CEPHALON INC (US) | 2012-09-19 | — | — | EP | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732447-B2 | such as 4-Pyridin-3-yl-2,5-dihydro-pyridazino[4,5-b]indol-1-one, used as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase, mixed lineage kinase (MLK) or cyclin-dependent kinase (CDK); treatment of angiogenic disorders and neurodegenerative diseases | CEPHALON, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CEPHALON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299061-A1 | Fused [d]pyridazin-7-ones | CDK5, CDK5R1, CDK7 | AGTR1 1664/4885MEN1 2202/4885KMT2A 1711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.